monkeypizza
Have you heard the one about the country with the death penalty for all crime? It just leads criminals to maximally try not to get caught, without regard to damage done [i.e. removing all witnesses to even the smallest crimes]. This isn't what you want; even within "negative" relationships both sides lose when you don't have a gradient of responses.
You risk making discourse difficult when you continue punishing people who are attempting to do the right after doing wrong for a while.
This seems more like a "you're with us or against us" trick.
"I care about protecting all children" is still neutral, right? But if someone popularized "ICAPBC", by your argument "ICAPAC" would innately become a shibboleth? Something doesn't seem right here, where neutral positions automatically get converted to dog-whistles without any proof.
It's hard to make self-modifying systems stable! I simultaneously want to preserve open debate, but also do want to reduce prevalence of views proposing easier rules to shut down debate (by defeating them in debate, not by law).
I don't think that is a very useful definition of tolerance. The only stable system here, if there is one, might be something like hardcoded self-defense actions, plus otherwise general tolerance. Not saying it's logically or morally consistent.
My main point was that the GGP's concept of tolerance, as something which can have no line at all, has never been the case in the US, and doesn't seem advisable, since his argument that any resistance is invalidation of tolerance would lead it to be easily destroyed.
When vaccines are in limited supply, expanding the number of people who receive some vaccine can reduce disease and mortality compared to concentrating vaccines in a subset of the population. A corollary of such dose-sparing strategies is that vaccinated individuals may have less protective immunity. Concerns have been raised that expanding the fraction of the population with partial immunity to SARS-CoV-2 could increase selection for vaccine escape variants, ultimately undermining vaccine effectiveness. We argue that although this is possible, preliminary evidence instead suggests such strategies should slow the rate of vaccine or immune escape. As long as vaccination provides some protection against escape variants, the corresponding reduction in prevalence and incidence should reduce the rate at which new variants are generated and the speed of adaptation. Because there is little evidence for efficient immune selection of SARS-CoV-2 during typical infections, these population-level effects are likely to dominate vaccine-induced evolution.
Conclusion: We propose that dose-sparing strategies, which could have large public health benefits, not be dismissed out of concern that they might promote immune escape in SARS-CoV-2. In fact, multiple lines of evidence suggest that expanded vaccination coverage could reduce the rate of immune escape, providing an additional benefit of dose sparing beyond its immediate impact on disease. These beneficial effects hinge on the assumption that vaccination provides some protection against variants of SARS-CoV-2, or in other words, that vaccine effectiveness against the variants is not zero under dose sparing. Another requirement is that other fitness-enhancing mutations not be exclusively linked to vaccine escape mutations. Both of these assumptions appear currently met. We encourage research to refine understanding of vaccine effectiveness, immune pressure, and the evolutionary dynamics of SARS-CoV-2, and to investigate this problem more thoroughly.
Author Affiliation Department of Ecology and Evolution, University of Chicago, Chicago, IL, USA
Department of Computer Science, University of Colorado Boulder, Boulder, CO, USA
BioFrontiers Institute, University of Colorado Boulder, Boulder, CO, USA
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA
Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA When vaccines are in limited supply, expanding the number of people who receive some vaccine can reduce disease and mortality compared to concentrating vaccines in a subset of the population. A corollary of such dose-sparing strategies is that vaccinated individuals may have less protective immunity. Concerns have been raised that expanding the fraction of the population with partial immunity to SARS-CoV-2 could increase selection for vaccine escape variants, ultimately undermining vaccine effectiveness. We argue that although this is possible, preliminary evidence instead suggests such strategies should slow the rate of vaccine or immune escape. As long as vaccination provides some protection against escape variants, the corresponding reduction in prevalence and incidence should reduce the rate at which new variants are generated and the speed of adaptation. Because there is little evidence for efficient immune selection of SARS-CoV-2 during typical infections, these population-level effects are likely to dominate vaccine-induced evolution.i.e. if you think 1x0%, 1x95% is better than 2x85%, do you not also think that 3x0%, 1x99% is better?
Their argument seems to be that we have 2 months of evidence that hospitalizations & negative effects are strongly reduced even by single doses, and we can reduce world-wide virus numbers by getting more 2x single dose resistances rather than single person double doses.
In this view, the risk of resistant strains would actually be less with 2 people at ~85% resistance, than one person with 95%. This is because if everyone had 85% resistance the virus reproduction rate would be <1, and it would completely die out, so wouldn't have an opportunity to evolve stronger strains - which it currently does have due to being prevalent all over the world.
While studies have not yet collected four months of data on vaccine effectiveness after the first dose, the first two months of real world effectiveness are showing sustained high levels of protection. ...
Short term sustained protection is consistent with immunological principles and vaccine science where it is not expected to see rapid waning of a highly effective vaccine in adults over a relatively short period of time. Extending the interval between doses was shown to be a good strategy through modelling, even in scenarios considering a six month interval and in theoretical scenarios where waning protection was considered.
NACI recommends that in the context of limited COVID-19 vaccine supply, jurisdictions should maximize the number of individuals benefiting from the first dose of vaccine by extending the interval for the second dose of vaccine to four months.
So basically, it makes theoretical sense, looks beneficial in total, so let's consciously adjust the vaccine administration regime we studied.Canadian government switches to support for first doses first
2. The US doesn't.
Your other points stand, but this core difference still matters.
I think the gains we would get from even a single day earlier application of First Doses First probably outweighs the pain caused to the FDA by Alex criticizing them.
https://www.businessinsider.com/blair-one-covid-19-vaccine-s...
People who haven't caught coronavirus yet are still likely to catch it and be at risk. That is, new people are still being infected and are likely to be for a few more months yet.
What calculation are you running to say that changes to policy which might increase first-dose protection are not worth making to protect them?
I'm not saying all rejection of convention is correct, obviously - but if you look at the specifics of the argument, not the status or credentials of the arguer, it seems more likely to come to a correct judgement.
By varying the parameters of the situation, could you be induced to change your view? i.e. vary CFR up to 1%, 10%, 50% - given that you acknowledge that the natural experiments we are observing from single-dose administration suggest most of the immunity granted by a vaccine is in the first dose - at what point do you budge?
If you admit that for a 50% CFR, you would not insist on following the established standard of care, then the question is where is the border for you, where your recommendation flips, and you consider early end to quarantine, reduced life loss, to be worth moral hazard of ad-hoc decisions, or not following the standard of care would bring?
giving 2 doses to one person over 65, and nothing to another other person over 65
giving one dose each to two 65+ people
We have evidence that total harm prevention under the second case is higher than the first case, and it also makes perfect logical sense, and there are public health officials confirming this.On the other hand we have tradition, custom, specific tests.
Say vaccines were tested based on administration in a blue room, but weren't tested in a room painted red. Why are you able to assert without tests that the room color is irrelevant, but are asking for proof that giving two people 85% resistance is better than one person with 95%, when all the evidence supports it? What is leading to wanting to strictly adhere to the exact tested procedure? How do you square your disagreement with the public health officials actively investigating this issue in the linked posts?
Michael Osterholm, Regents Professor, McKnight Presidential Endowed Chair in Public Health, the director of the Center for Infectious Disease Research and Policy (CIDRAP) and state epidemiologist for the Minnesota Department of Health:
…Imagine you are setting across the table from two people both of whom are 65 or older, both with underlying health conditions. You have two doses of vaccine, one in each hand. And you say to them I can give two doses to you or to you but then the other person gets nothing. Or I can give one dose to both of you. And this is what I know. At the very least, one dose is likely to prevent serious illness, hospitalization and death. Two doses will probably even prevent clinical disease with B.1.1.7. But the other one of you; if you get infected with this virus, which I think substantial numbers of Americans will, things are not looking good for you. What do you want me to do?
If that is your Mom or Dad. Your Grandpa or Grandma. What would you do?
This is where the rubber meets the road. I think if the data bears it out we can save so many lives in the upcoming weeks and we are missing that opportunity.
I have already made my choice. I am postponing my second dose. I want my second dose. But I am confident that I can wait. And I can only hope that my second dose, which I have just deferred, will go to someone who it will save their life. It will make a totally different world for that family.
You know some could argue that this could be the end of my career. But I could not sleep with myself at night if I didn’t do this. I just know in my heart of hearts that this is something we must do if we are going to save lives.
https://marginalrevolution.com/marginalrevolution/2021/02/os...This is more about looking at the ability of our systems to change their response in emergencies; why are obvious things so hard to do, when they both fully make sense, and are supported by an interested group of experts, against a larger but less interested group of conventional, rule-following experts?
At 20/dose, companies could produce N. At 30/dose they could probably find a way to produce more (perhaps by spending money to retrofit an old machine, which at 20/dose wouldn't have been worth it). And at 100/dose they can afford to fly the device manufacturer out to personally oversee sped-up installation.
"If we paid Tesla 2x as much per car, could they really not produce more cars?"
They also fail to privileging the status quo - "If we paid Tesla half as much money, would they produce fewer cars?"
Obviously, they would. Money influences how easily they can produce cars. At the margin there must be decisions related to turning money into efficiency every day. And the same thing must apply for vaccines. The best vaccine expert in the world asked for a yearly sabbatical - 200k wasn't enough to keep them. Double that to 400k? Oh actually it can wait til next year.
The question for people who deny money's ability to produce more vaccines is: why do you admit that any lower price for a vaccine would reduce supply - but you deny that any higher price would increase supply. What magic is this?
This would be a truer test of "Do companies really, really not have any extra capacity? Or are they just allocating resources according to profit maximization, not to maximum effort?"
This is what normal markets ARE - companies take risks and investments for a chance at profit. The government could fake the system by offering high rewards... or we could just let companies do reasonable things like sell 20% of their output at market price.
This reminds me of the CCP in the 1950s where most private land was socialized... and farmers ended up putting all their effort into their private plots, because that was the only work they could do that they'd actually get to keep.